Article: Nicotinamide Riboside Prevents Age-Related Hearing Loss: Preclinical Findings

PrevNext
Healthy Aging & Longevity Preclinical Sensory (Auditory/Optical)

Nicotinamide Riboside Prevents Age-Related Hearing Loss: Preclinical Findings

Synopsis

Age‐related hearing loss (ARHL) is the most common sensory disability associated with human aging. Yet, there are no approved measures for preventing or treating this debilitating condition. Long-term NR administration in two mouse strains prevented progression of ARHL, especially at high frequencies. NR restored cochlear NAD+ levels, improved synaptic transmission between auditory neurons and hair cells, and upregulated lipid droplet proteins CIDEC and PLIN1 via PPAR signaling. These findings support NR's potential as a safe, long-term therapy for ARHL with novel effects on cochlear lipid metabolism.

Journal

Aging Cell

Share

Read more

COVID/Long-COVID

Nicotinamide Riboside Restores NAD+ Metabolism and Improves Recovery in COVID-19: Preclinical Findings

SynopsisSevere COVID-19 initially causes lung infection and inflammation. Some patients develop Post-Acute Sequelae of COVID (PASC), experiencing ongoing lung problems, fatigue, and cognitive issue...

Read more
Diabetes

Nicotinamide Riboside Protects Against Diabetic Kidney Disease: Preclinical Findings

SynopsisDiabetic kidney disease (DKD) is a leading cause of kidney failure, linked to inflammation and mitochondrial dysfunction. This study evaluated whether boosting NAD+ metabolism via nicotinam...

Read more